Carlos Martin

Carlos Martin MD, PhD. Professor of Microbiology, Faculty of Medicine, University of Zaragoza, Spain. He is a member of the Steering Committee of TBVI, with more than 30 years of experience in mycobacterial genetics and molecular epidemiology of TB. He and his team aim to develop the new TB vaccine candidate MTBVAC today in Phase 3 in collaboration with Biofabri, the industrial partner of the University of Zaragoza and with the support of TBVI and IAVI.

Email carlos@unizar.es

Twitter: @CarlosMTBVAC